Nonacidic Chemotype Possessing N-Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists

被引：12
|
作者：
Teno, Naoki [1 ,2 ]
Yamashita, Yukiko [3 ]
Ig, Yusuke [3 ]
Fujimori, Ko [4 ]
Une, Mizuho [1 ,3 ]
Nishimaki-Mogami, Tomoko [5 ]
Hiramoto, Takie [1 ]
Gohda, Keigo [6 ]
机构：
[1] Hiroshima Int Univ, Grad Sch Pharmaceut Sci, 5-1-1 Hirokoshingai, Kure, Hiroshima 7370112, Japan
[2] Hiroshima Int Univ, Fac Clin Nutr, 5-1-1 Hirokoshingai, Kure, Hiroshima 7370112, Japan
[3] Hiroshima Int Univ, Fac Pharmaceut Sci, 5-1-1 Hirokoshingai, Kure, Hiroshima 7370112, Japan
[4] Osaka Univ Pharmaceut Sci, Fac Pharmaceut Sci, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan
[5] Natl Inst Hlth Sci, Setagaya Ku, Kamiyoga 1-18-1, Tokyo 1588501, Japan
[6] Kansai CAMM Kansai, Comp Aided Mol Modeling Res Ctr, 3-32-302 Tsuto, Nishinomiya, Hyogo 6638241, Japan
来源：
ACS MEDICINAL CHEMISTRY LETTERS | 2018年 / 9卷 / 02期
基金：
日本学术振兴会;
关键词：
FXR antagonists; benzimidazole scaffold; N-acylated piperidine; triglyceride accumulation; ORPHAN NUCLEAR RECEPTOR; BILE-ACID; ADIPOCYTE DIFFERENTIATION; IDENTIFICATION; OPTIMIZATION; DISCOVERY; LIGANDS; HOMEOSTASIS; DERIVATIVES; MODULATORS;
D O I：
10.1021/acsmedchemlett.7b00363
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Famesoid X receptor (FXR) plays a major role in the control of cholesterol metabolism. Antagonizing transcriptional activity of FXR is an effective means to treat the relevant metabolic syndrome. Some of antagonists so far have the charged functions; however, they may negatively affect the pharmacokinetics. We describe herein a structure activity relationship (SAR) exploration of nonacidic FXR antagonist 6 focusing on two regions in the structure and biological evaluation of nonacidic 10 with the characteristic N-acylated piperidine group obtained from SAR studies. As the robust affinity to FXR is feasible with our nonacidic analogue, 10 is among the most promising candidates for in vivo testing.
引用
收藏
页码：78 / 83
页数：6
相关论文
共 35 条
  • [11] Identification of potent farnesoid X receptor (FXR) antagonist showing favorable PK profile and distribution toward target tissues: Comprehensive understanding of structure-activity relationship of FXR antagonists
    Teno, Naoki
    Yamashita, Yukiko
    Masuda, Arisa
    Iguchi, Yusuke
    Oda, Keisuke
    Fujimori, Ko
    Hiramoto, Takie
    Nishimaki-Mogami, Tomoko
    Une, Mizuho
    Gohda, Keigo
    BIOORGANIC & MEDICINAL CHEMISTRY, 2019, 27 (11) : 2220 - 2227
  • [12] N-acylated α-(3-pyridylmethyl)-β-aminotetralin antagonists of the human neuropeptide YY5 receptor
    McNally, JJ
    Youngman, MA
    Lovenberg, TW
    Nepomuceno, D
    Wilson, S
    Dax, SL
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (15) : 1641 - 1643
  • [13] Identification of trisubstituted-pyrazol carboxamide analogs as novel and potent antagonists of farnesoid X receptor
    Yu, Donna D.
    Lin, Wenwei
    Forman, Barry M.
    Chen, Taosheng
    BIOORGANIC & MEDICINAL CHEMISTRY, 2014, 22 (11) : 2919 - 2938
  • [14] An improved synthesis of 6α-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR)
    Yu, Donna
    Mattern, Daniell L.
    Forman, Barry M.
    STEROIDS, 2012, 77 (13) : 1335 - 1338
  • [15] TISSUE DISTRIBUTION OF EDP-305, A HIGHLY SELECTIVE AND POTENT FARNESOID X RECEPTOR (FXR) AGONIST, IN PRECLINICAL SPECIES
    Huang, Meng
    Jiang, Li-Juan
    Dai, Peng
    Ronsheim, Matthrew
    Or, Yat Sun
    DRUG METABOLISM AND PHARMACOKINETICS, 2020, 35 (01) : S34 - S34
  • [16] Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis
    Zhang, Chenlu
    Liu, Yameng
    Wang, Ying
    Ge, Xie
    Jiao, Tingying
    Yin, Jianpeng
    Wang, Kanglong
    Li, Cuina
    Guo, Shimeng
    Xie, Xin
    Xie, Cen
    Nan, Fajun
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (19) : 13452 - 13472
  • [17] Expanding the Library of 1,2,4-Oxadiazole Derivatives: Discovery of New Farnesoid X Receptor (FXR) Antagonists/Pregnane X Receptor (PXR) Agonists
    Finamore, Claudia
    Festa, Carmen
    Fiorillo, Bianca
    Di Leva, Francesco Saverio
    Roselli, Rosalinda
    Marchiano, Silvia
    Biagioli, Michele
    Spinelli, Lucio
    Fiorucci, Stefano
    Limongelli, Vittorio
    Zampella, Angela
    De Marino, Simona
    MOLECULES, 2023, 28 (06):
  • [18] Scaffold extension-based discovery of novel, highly potent and selective small molecule farnesoid X receptor (FXR) agonists
    Grether, Uwe M.
    Benson, Gregory M.
    Bleicher, Konrad H.
    Blum, Denise
    Chaput, Evelyne
    Gardes, Christophe
    Hartman, Peter
    Kuhn, Bernd
    Plancher, Jean-Marc
    Martin, Rainer E.
    Richter, Hans G. F.
    Rudolph, Markus
    Schuler, Franz
    Taylor, Sven
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 241
  • [19] Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists
    Schmidt, Jurema
    Schierle, Simone
    Gellrich, Leonie
    Kaiser, Astrid
    Merk, Daniel
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (14) : 4240 - 4253
  • [20] Discovery of XL335 (WAY-362450), a Highly Potent, Selective, and Orally Active Agonist of the Farnesoid X Receptor (FXR)
    Flatt, Brenton
    Martin, Richard
    Wang, Tie-Lin
    Mahaney, Paige
    Murphy, Brett
    Gu, Xiao-Hui
    Foster, Paul
    Li, Jiali
    Pircher, Parinaz
    Petrowski, Mary
    Schulman, Ira
    Westin, Stefan
    Wrobel, Jay
    Yan, Grace
    Bischoff, Eric
    Daige, Chris
    Mohan, Raju
    JOURNAL OF MEDICINAL CHEMISTRY, 2009, 52 (04) : 904 - 907
1234